Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival - Wikidata - wikimedia - TriplyDB

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

http://www.wikidata.org/entity/Q33621327

about

Management of low-grade glioma.Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma.Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis.Insulin and glucagon regulate pancreatic α-cell proliferation Medical therapy of gliomas.A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.Ciliary transport regulates PDGF-AA/αα signaling via elevated mammalian target of rapamycin signaling and diminished PP2A activity.Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma.The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome The combination of novel targeted molecular agents and radiation in the treatment of pediatric gliomas.Prognostic role of phospho-PRAS40 (Thr246) expression in gastric cancer Epilepsy in patients with a brain tumour: focal epilepsy requires focused treatment.The molecular landscape of diffuse glioma and prospects for biomarker development.Tissue microarray evidence of association between p16 and phosphorylated eIF4E in tonsillar squamous cell carcinoma.Glioblastoma: pathology, molecular mechanisms and markers.Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas.Antiproliferative effects of γ-secretase inhibitor, a Notch signalling inhibitor, in multiple myeloma cells and its molecular mechanism of action.Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors.mTORC1 signaling in primary central nervous system lymphoma.Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas.Hypomethylation of CNTFRα is associated with proliferation and poor prognosis in lower grade gliomas.PRAS40 acts as a nodal regulator of high glucose-induced TORC1 activation in glomerular mesangial cell hypertrophy.TET1 exerts its tumour suppressor function by regulating autophagy in glioma cells.Phosphorylated ribosomal protein S6 correlation with p21 expression and inverse association with tumor size in oral squamous cell carcinoma.Functional network analysis of gene-phenotype connectivity associated with temozolomide.High LC3/Beclin Expression Correlates with Poor Survival in Glioma: a Definitive Role for Autophagy as Evidenced by In Vitro Autophagic Flux.Overexpression of mTOR and p(240-244)S6 in IDH1 Wild-Type Human Glioblastomas Is Predictive of Low Survival.Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades.Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.Ridaforolimus for patients with progressive or recurrent malignant glioma: a perisurgical, sequential, ascending-dose trial.Cerebellar Ganglioglioma in Childhood: Histopathologic Implications for Management During Long-term Survival: A Case Report.Immunohistochemical evaluation of the mTOR pathway in intra-oral minor salivary gland neoplasms.Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas.Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma

P2860

Q30436353-32209624-2506-4A72-AE96-22C3CA516274 Q33275031-4934930B-0907-483F-AFC7-6419436694D4 Q33275157-D944E4F8-E7B6-4F3E-9847-94B24A7375FA Q33808713-37FEB58B-1AE4-4D4D-BF88-0A8FD8137028 Q34218761-02EFB7D0-CB2C-4163-B4CE-370D8684E5F9 Q34818301-FE188344-1F98-4472-A51B-05710DC39A5D Q34960781-027442D0-DB05-447E-B7CC-689FEDC9EA29 Q35143738-DB397577-9CA1-44A6-960D-3E448C63436F Q35864082-EAC2D1FE-3851-461F-9A13-4F531886D152 Q35987253-17C7C624-910F-4071-A272-D685EFB4C02B Q36179171-E0C497EC-3A69-483A-B754-FD9BA89EC9D0 Q36833480-8E686954-4650-4DEB-A0B7-387D8978EA3A Q37636833-B8FFF103-DB52-4C27-8187-C76791577CBA Q37968607-1DB61A44-5628-4162-83ED-0BDE070F5C7A Q38155656-81F1445C-406B-4507-B112-18EA280FAF6B Q38408862-E4343B38-2A11-4A5C-BEFC-456FD1EDC400 Q38460865-F6009F5A-5101-4869-A38B-BEFDF1C255D4 Q38958545-0E3FCBB3-2FA6-4672-A8E4-815B1FF8603F Q39128267-FB0CAAA3-F570-4CD5-9C5C-709C7F3E60BB Q39365297-4F4E2477-BCAC-4BB8-B30F-2D3659B2C6AF Q39501076-F7535A55-9316-4C5E-B6B0-71C5FFAABDDE Q39593159-57715EFD-51F0-46A0-A378-3082444A481A Q40101428-8FE95D5C-19C8-4D3D-9B68-6B58A43B5875 Q41204421-47DA294E-EA86-4F4F-BFA5-E331FC90B424 Q42713697-38648889-861B-4E3B-9037-D4F770BB688D Q47129492-27F930E9-06A4-4102-97B6-FD3057E099C2 Q47202432-C69FD65E-85D5-4EC5-A9D5-1D06D64D47EE Q47258480-B304F563-0AC2-4A73-9B7D-C78F51C14BD0 Q47664663-3AC7CE1F-45FD-4B5E-B75C-A1D5333AB113 Q47867724-AB2C3A89-EF60-45DE-AA43-457A30C378E2 Q48450513-07B0A161-3977-4066-BCE1-2CCB719E0642 Q48523422-DEA9AE02-25B4-43F5-A374-C7A9E9CEF55A Q48806296-EB057183-668A-4A03-B0DC-7F6BBCFE7D31 Q50054743-71723AD5-DF70-4D24-A5DB-2FB9F3F0588E Q54194644-EB93A9B0-CF7F-430D-ABB4-DE2AB3AD9CBB Q54647171-D47DC7A2-F485-47E4-A64A-46BBF85549A2 Q58731660-55D0D8F4-D8F8-47C6-A129-3BCE8E59B332

P2860

Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

http://www.wikidata.org/entity/Q33621327

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Activation of PI3K/mTOR pathwa ...... and predicts patient survival

@ast

Activation of PI3K/mTOR pathwa ...... and predicts patient survival

@en

type

label

Activation of PI3K/mTOR pathwa ...... and predicts patient survival

@ast

Activation of PI3K/mTOR pathwa ...... and predicts patient survival

@en

prefLabel

Activation of PI3K/mTOR pathwa ...... and predicts patient survival

@ast

Activation of PI3K/mTOR pathwa ...... and predicts patient survival

@en

P1433

Q33621327-81F7348F-031A-41F2-BC41-59F4B048B76F

P1476

Q33621327-6DAB3C90-531F-4B45-852C-17D170CA56F2

P2093

Q33621327-22A6282E-2578-4B09-B174-1B29E4DF87B5

Q33621327-44CD86A5-1170-4E16-8424-51BF2A3369FD

Q33621327-69DB6460-7CF1-40F9-9EA5-A6CC762D8BF3

Q33621327-6C7F011B-0645-4CC8-BED4-8DA939975EED

Q33621327-762C5188-EB52-40F1-A091-EAC38EDE3875

Q33621327-7FE0592E-6A97-4632-870A-A62571096FD2

Q33621327-822A7B5C-866E-40C4-8B8C-04BD479E030F

Q33621327-85623ECE-4D69-46F2-B5B0-B349B254AF21

Q33621327-8F6131CA-00DF-4946-8429-0C26DC6881AC

Q33621327-A1EA8AF5-8BFB-4F8D-94B6-11543F5170CE

P2860

Q33621327-004549BC-00C9-41C2-93B8-3D1CD588CE9B

Q33621327-111FA7EF-135F-4F88-AB38-4031BE6EB699

Q33621327-2830D616-2DEC-4393-AADA-0C6E8379903B

Q33621327-2BACC80F-F449-45B7-AECB-D55512681B49

Q33621327-412157BD-FAFF-4893-A6A9-51A152D75393

Q33621327-5345F669-7C7D-4869-B34E-376564707261

Q33621327-59EEB5C2-6582-481A-A707-BE11FE394F94

Q33621327-63F65173-A4E6-4360-8101-ED193E92D931

Q33621327-9B923195-B705-4369-9B06-06D8DB4C2464

Q33621327-9D05E251-ECB2-4006-9196-DF5C84508FD9

P2888

Q33621327-1BBA5C52-28E8-4C6B-97C3-038605A1120A

P304

Q33621327-C1B37695-B4E7-4F43-AD07-96AD81FC3A34

P31

Q33621327-1BEBCF37-2B1A-4759-8168-9C6990FE9B56

P356

Q33621327-BCDC2FD7-D234-4C9D-9CC0-065D5DE6F926

P433

Q33621327-134A2C6A-FB4D-4168-A6CF-AB4412BC601C

P478

Q33621327-9B2795A7-6D70-4E5B-8E04-5E58F2BEF675

P577

Q33621327-3F467518-F1A2-4CE5-821E-6DF5A9949AE1

P5875

Q33621327-33065450-E591-4ED1-8890-09CA9EE72689

P6179

Q33621327-C2B0033A-0BA1-4BFF-B94B-12713208DCF3

P698

Q33621327-2E5B21A8-5C54-4F8F-AF5D-79E457C5F1F0

P921

Q33621327-31ACB7AF-6AE8-4F6F-BA28-B3A061E9017A

P932

Q33621327-71F58EAB-807D-4179-9B8E-5565A66D0838

P356

S11060-009-0004-4

P1433

Journal of Neuro-Oncology

P1476

Activation of PI3K/mTOR pathwa ...... and predicts patient survival

@en

P2093

Daniel A Perez

http://www.w3.org/2001/XMLSchema#string

Daphne A Haas-Kogan

http://www.w3.org/2001/XMLSchema#string

David Stokoe

http://www.w3.org/2001/XMLSchema#string

John K Wiencke

http://www.w3.org/2001/XMLSchema#string

Justin S Smith

http://www.w3.org/2001/XMLSchema#string

Kathleen R Lamborn

http://www.w3.org/2001/XMLSchema#string

Mei-Yin Polley

http://www.w3.org/2001/XMLSchema#string

Michael D Prados

http://www.w3.org/2001/XMLSchema#string

Mitchel S Berger

http://www.w3.org/2001/XMLSchema#string

Scott R Vandenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

The TOR pathway: a target for cancer therapy

Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.

Role of S6 phosphorylation and S6 kinase in cell growth.

The role of mTOR in the management of solid tumors: an overview.

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p

mTOR-understanding the clinical effects.

Therapeutic targets: MTOR and related pathways.

Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.

P2888

s11060-009-0004-4

P304

33-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-009-0004-4

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26765180

http://www.w3.org/2001/XMLSchema#string

P6179

1036194195

http://www.w3.org/2001/XMLSchema#string

P698

19705067

http://www.w3.org/2001/XMLSchema#string

P921

P932

2814032

http://www.w3.org/2001/XMLSchema#string